← Eichor
Study identifier: NCT07551492 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease

Condition: Atherosclerotic Cardiovascular Disease  ·  Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

PhasePhase 3
Planned participants9262
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of the study is to evaluate the impact of HRS9531 on major adverse cardiovascular events (MACE) in patients with atherosclerotic cardiovascular disease. This study adopts an event-driven design and ends when the target number of the primary endpoint event is reached.

This description comes directly from the study's public registry record.

Talk to the study team

Sheng Qi  ·  +8613482562074  ·  Sheng.qi@hengrui.com

Always discuss trial participation with your own doctor first.

Locations (1)

Fuwai Hospital, CAMS&PUMCBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07551492